Both PF-06465469 and ibrutinib significantly decreased PD-1 and LAG-3 expression (Figure 7, I and J, and Supplemental Figure 7, I–N), suggesting a potential decrease of exhaustion in CLL-CAR-T cells. This evidence concerns the gene PDCD1 and B-cell chronic lymphocytic leukemia.